In this regard, inhibitors acting on the RHO/ROCK-mediated pathway are becoming a promising therapeutic approach for vascular endothelial growth factor (VEGF)-induced angiogenesis in the context of tumor progression and invasion (van der Meel et al., 2011; Chen et al., 2014). This evidence concerns the gene RHO and neoplasm.